Inoviq Ltd · ASX:IIQ
Inoviq — Shareholder Meeting (November 2022)
25 slides from Inoviq's shareholder meeting presentation, Nov 28, 2022
Slide 1: AGM Presentation
AGM Presentation 28 November 2022 ASX: IIQ
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) Actual results, performance or achievements could be significantly different from those based on information available to it as at the date of this presentation. This presentation expressed in, or implied by
Slide 3: Vision
Vision Our vision is to enable earlier and more accurate detection of cancer and other diseases to improve treatment options, patient outcomes and survival 3
Slide 4: INOVIQ summary
INOVIQ summary Next-generation exosome capture tools and precision diagnostics Patented technology platforms for biomarker isolation and detection Products in-market for exosome research & bladder cancer $ Multi-product cancer diagnostics pipeline targeting large global markets Compelling early data
Slide 5: Key company metrics
Key company metrics $13.5m 92,018,702 $0.575 $52.9m Cash at bank1 Ordinary shares2 Share price2 Market capitalisation2 Share price performance A$607k 34.8% Ave monthly cash burn Top 20 holders2 5 1. Cash at 30 Sep 22 | 2. As at 25 Nov 2022.
Slide 6: Broad development pipeline provides multiple shots on goal
Broad development pipeline provides multiple shots on goal ASSAY CLINICAL PRODUCT INDICATION PLATFORM USE RESEARCH DEVELOPMENT DEVELOPMENT REGISTRATION hTERT1 Bladder Cancer ICC Adjunct to cytology In-market EXO-NET-RUO Exosome Capture Device Research tool In-market Exosome-OC2 (OCRF-7) Ovarian
Slide 7: Multiple tests for different cancers and uses in the diagnostic pathway
Multiple tests for different cancers and uses in the diagnostic pathway BEFORE DIAGNOSIS AFTER DIAGNOSIS SCREENING DIAGNOSIS TREATMENT MONITORING SELECTION Test use Earlier detection in Aiding and confirming Staging and triage-to- Monitoring asymptomatic people diagnosis treatment treatment response
Slide 8: Ovarian cancer
Ovarian cancer UNMET NEED for earlier and more accurate 5-year Survival by Stage at Diagnosis tests for OC detection and monitoring Normal Stage 1 Stage 2 Stage 3 Stage 4 Healthy ovaries Confined to Spread within Spread within Spread to other prevalence 823k 45% ovaries pelvis abdomen organs $1.9b I
Slide 9: Exosome-based ovarian cancer screening test
Exosome-based ovarian cancer screening test Collaboration with UQ to develop world-first exosome-based ovarian cancer screening test1 AA OCRF-7 OCRF-7 BB CA-125 • EXO-NET technology used for fast and accurate 1.0 1.0 1.0 1.0 and scalable exosome isolation 0.8 0.8 0.8 0.8 predictive predictive Poster
Slide 10: Exosome-based OC test | Plans
Exosome-based OC test | Plans Next-steps 1. Ovarian Cancer 97 Study: To establish that EXO-NET is fit-for-purpose for the downstream analysis of plasma extracellular vesicle associated microRNA and protein and for use in MRFF Ovarian Cancer Screening Study (UQ) 2. OC 250 Study: Analytical Validation
Slide 11: SubB2M-based SPR test for cancer risk assessment
SubB2M-based SPR test for cancer risk assessment • POC data in case-control studies showed the SubB2M-based SPR test detected: o Ovarian Cancer at 100% sensitivity and 100% specificity across all stages (n = 69) 1,2 o Breast Cancer at 95% sensitivity and 100% specificity across all stages (n = 118)
Slide 12: Breast cancer
Breast cancer UNMET NEED for earlier and more accurate 5-year Survival by Stage at Diagnosis tests for BC detection and monitoring prevalence 7.8m $4.2b incidence 2.3m Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 BREAST CANCER deaths 685k 85% Non-invasive Invasive tumour Tumour <5cm +/- Tumour >5cm & Spr
Slide 13: SubB2M-based Breast Cancer monitoring test
SubB2M-based Breast Cancer monitoring test • SubB2M-based immunoassay development, optimisation and BC 95 Study: Breast Cancer Clinical Study validation underway at ResearchDx1,2 • Commenced breast cancer clinical study (BC95) to evaluated performance of SubB2M-CA15.3 by cancer stage p= 0.005 • Inte
Slide 14: SubB2M Breast Cancer monitoring study
SubB2M Breast Cancer monitoring study Intended use: A blood test to aid in monitoring breast cancer recurrence Prospectively Collected Retrospectively Analysed Longitudinal Breast Cancer Study Study Design Prospective Longitudinal Clinical Cohort Study Objective CA15.3 is still a widely used test fo
Slide 15: SubB2M Breast Cancer monitoring study (cont.)
SubB2M Breast Cancer monitoring study (cont.) Intended use: A blood test to aid in monitoring breast cancer recurrence 2022 2023 Post-treatment histologically/ pathologically confirmed diagnosis of breast cancer (n=200) Serum samples collected at 3,6,12,24,48 months Neu5Gc-CA15.3 & CA15.3 concentrat
Slide 16: Commercialisation strategy
Commercialisation strategy Diagnostics: Laboratory Developed Test In Vitro Diagnostic (LDT) (IVD) • Initial market entry in US CLIA FDA 510k clearance / PMA • Via LDT to IVD commercialisation pathways approval • Contracted ResearchDx for development & Development & validation in a Larger-scale clini
Slide 17: Market potential | Screening and monitoring
Market potential | Screening and monitoring Eligible screening Screening market Eligible monitoring Monitoring market Statistics1 population2 size3 population4 size5 11.5 1.7 4.0 1.2 Ovarian cancer incidence 28.0 18.2 188.3 52,638 60.4 25.1 Ovarian 119m USD 36b 367k USD 55m 54.7 cancer 167.3 16.2 Ov
Slide 18: Exosomes | Diagnostic and therapeutic potential
Exosomes | Diagnostic and therapeutic potential Exosomes are small extracellular vesicles (sEVs; 30-150nm) released from most cells, including cancer cells, into body fluids (plasma, saliva, urine, CSF) EXOSOMES contain biomolecules (DNA, RNAs, proteins) and deliver these “messages” between cells Ex
Slide 19: EXO-NET I Exosome isolation tools
EXO-NET I Exosome isolation tools • EXO-NET pan-exosome capture is a ‘research use only’ (RUO) product for isolation of exosomes from body fluids • Meets and unmet need for rapid, efficient and scalable isolation of exosomes • Suitable for biomarker discovery, research & development phases of future
Slide 20: EXO-NET | Speed, purity and yield advantages
EXO-NET | Speed, purity and yield advantages FAST Easy and convenient workflow with EV capture in 15 minutes Optimal solution for very low volume and rare samples from plasma, urine, SAMPLE VERSATILITY saliva HIGH YIELD High yield and capture of EVs from various biofluids Reduced co-isolation of con
Slide 21: EXO-NET I Efficient Isolation of plasma EV derived RNAs
EXO-NET I Efficient Isolation of plasma EV derived RNAs EXONET outperforms or is equivalent to 4 EXONET comparison to 4 commercial kits 45.00 commercial EV isolation kits for recovery of EV micro RNA (miRNA) and messenger (mRNA) as indicated by lower CT values.1,2 40.00 Mean CT Value 35.00 30.00 “Th
Slide 22: Key achievements of 2022 and catalysts for 2023
Key achievements of 2022 and catalysts for 2023 PoC results for Balance sheet Brands unified ResearchDx UQ collaboration to EXO-NET US sales SubB2M-CA125 strengthened: under new engaged for dev develop world-first force engaged to Several key test for OC $18.4m raised name: INOVIQ / validation of ex
Slide 23: Outlook
Outlook Focus on execution, capability building and growth •Complete clinical studies for SubB2M-based tests for BC & OC monitoring Dx pipeline advancement •Validate SubB2M-based SPR test for risk assessment across multiple cancers •Progress case-control studies for exosome-based OC test •Develop an
Slide 24: Board and Management
Board and Management DR GEOFF CUMMING PhD MAX JOHNSTON PHILIP POWELL Prof ALLAN CRIPPS AO PhD Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Healthcare and biotechnology director with Healthcare industry director and international Healthcare industry dire
Slide 25: Contacts
Contacts INOVIQ Ltd Dr Leearne Hinch Chief Executive Officer 23 Normanby Road Notting Hill VIC 3168 e. lhinch@inoviq.com Australia m. +61 400 414 416 p. +61 3 9548 7586 e. info@inoviq.com w. www.inoviq.com 25